A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate in Moderate-To-Severe Alopecia Areata

This study found that a high proportion of alopecia areata patients experienced a relapse, typically within one year, with more extensive initial scalp involvement predicting an earlier return of the disease.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This review found insufficient evidence to determine methotrexate's effectiveness for maintaining regrowth in extensive alopecia areata, and suggests its potential role in inducing regrowth when combined with corticosteroids.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This review highlights the diverse prognoses and limited long-term efficacy of current alopecia areata treatments, discussing existing and emerging therapies—including biologics—and proposing an algorithmic management approach based on specific disease characteristics.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.

In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.

This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.

This letter discusses the psychological impact of alopecia areata, highlighting its association with increased depression and anxiety, but reports no new clinical findings.

This study investigated alkaline phosphatase activity in scalp biopsies from patients with alopecia areata and totalis, but provides no new conclusive clinical results.